Systemic therapy and targeted agents in advanced esophageal cancer

Mark A. Lewis, Harry H. Yoon

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter summarizes recent progress in the treatment of patients with advanced adenocarcinoma of the esophageal and gastroesophageal junction, with a focus on the clinical development of systemic targeted agents. To date, monoclonal antibodies targeting the human epidermal growth factor receptor (HER) 2 (trastuzumab) and tumor-related angiogenesis (ramucirumab) have been shown to improve overall survival in Phase 3 trials of esophagogastric adenocarcinoma, whereas a lack of meaningful efficacy has been demonstrated by epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (cetuximab, panitumumab) and small molecule inhibitors (gefitinib). Benefit from the dual EGFR/HER2-targeted tyrosine kinase inhibitor, lapatinib, appears to be limited, although responsive subpopulations may be identified. Success in further development of anti-cancer therapies in advanced disease will likely rely on focusing patient enrollment on those with actionable molecular targets.

Original languageEnglish (US)
Title of host publicationEsophageal Cancer and Barrett's Esophagus
PublisherWiley-Blackwell
Pages251-264
Number of pages14
ISBN (Electronic)9781118655153
ISBN (Print)9781118655207
DOIs
StatePublished - Dec 12 2015

Keywords

  • EGFR
  • Esophageal adenocarcinoma
  • Esophageal cancer
  • Gastroesophageal junction adenocarcinoma
  • Gastroesophageal junction cancer
  • HER2
  • Ramucirumab
  • Targeted therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Systemic therapy and targeted agents in advanced esophageal cancer'. Together they form a unique fingerprint.

Cite this